ruxolitinib   

GtoPdb Ligand ID: 5688

Synonyms: (R)-ruxolitinib | INC424 | INCB 18424 | INCB018424 | Jakafi® | Jakavi®
ruxolitinib is an approved drug (FDA (2011), EMA (2012))
Compound class: Synthetic organic
Comment: Ruxolitinib is a Type-1 kinase inhibitor and was first approved by the US FDA in 2011. Ruxolitinib has high potency against Janus kinases 1 and 2 (JAK1, JAK2), as well as against the related family member, tyrosine kinase 2 (TYK2) [3]. Inhibitory activity against JAK3 is only slightly reduced compared to the other three family kinases.
Marketed formulations may contain ruxolitinib phosphate (PubChem CID 25127112).
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: ruxolitinib

2D Structure
Click here for structure editor
Physico-chemical Properties
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 4
Topological polar surface area 83.18
Molecular weight 306.16
XLogP 2.7
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Canonical SMILES N#CCC(n1ncc(c1)c1ncnc2c1cc[nH]2)C1CCCC1
Isomeric SMILES N#CC[C@@H](n1ncc(c1)c1ncnc2c1cc[nH]2)C1CCCC1
InChI InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1
InChI Key HFNKQEVNSGCOJV-OAHLLOKOSA-N

For advanced searching click here to open chemical structure editor

Similar Ligands
No closely similar ligands found - try using advanced searching to find other ligands.